Hercules Capital and SVB Provide $60MM Term Loan to SCYNEXIS
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.
May 17, 2021
Armentum Partners | Bryan Jadot | Hercules Capital | Marco Taglietti | SCYNEXIS | Silicon Valley Bank | Tom Gordon
Ian Koplin